WO2001010462A1 - Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies - Google Patents
Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies Download PDFInfo
- Publication number
- WO2001010462A1 WO2001010462A1 PCT/US2000/040459 US0040459W WO0110462A1 WO 2001010462 A1 WO2001010462 A1 WO 2001010462A1 US 0040459 W US0040459 W US 0040459W WO 0110462 A1 WO0110462 A1 WO 0110462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- nhl
- bone marrow
- chimeric
- administered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Definitions
- the present invention relates to a method of reducing the number of cancerous B cells in the bone marrow of a patient having a B cell lymphoma prior to radioimmunotherapy comprising administration of an anti- CD20 antibody.
- Combined therapeutic methods of treating a patient having lymphoma with associated bone marrow involvement are also encompassed.
- Radioimmunotherapy of B cell lymphoma is limited by marrow involvement, i.e., infiltration of the bone marrow by cancerous B lymphocytes. This complicates radioimmunotherapy in two regards: (1) antibody binding ,to diseased cells in the marrow will deliver a dose of radiation to the marrow thereby causing unwanted myelosuppression; and (2) marrow crowding of normal cells and progenitors will weaken healthy marrow reserves so that patients may actually be closer to grade 3 or 4 cytopenias than would be the case in patients without marrow involvement.
- the patient may be less tolerant to radioimmunotherapy, e.g., with B cell depleting antibody conjugated to a radioisotope such as 90 Y or 131 I .
- radioimmunotherapy e.g., with B cell depleting antibody conjugated to a radioisotope such as 90 Y or 131 I .
- a radioisotope such as 90 Y or 131 I .
- patients with greater than 25% bone marrow involvement are generally excluded from treatment with radioimmunotherapy.
- IDEC-Y2B8 radioimmunotherapy baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry. Blood 1998 Supplement November, 92(10): 417a (1721) Poster Board #/ Session: 393-III) .
- the present invention relates to methods of treating patients having B cell lymphoma accompanied by bone marrow involvement comprising administering a monoclonal antibody or fragment thereof such that said bone marrow involvement is reduced or alleviated.
- the invention encompasses methods of reducing the number of cancerous B cells in the bone marrow of a patient having non-Hodgkin' s lymphoma prior to radioimmunotherapy comprising administering to said patient an effective amount of a therapeutic antibody.
- the methods are also useful for reducing bone marrow involvement prior to administration of antibodies labeled with cytotoxic moieties such as toxins, or any immunotherapeutic which could damage healthy bone marrow progenitors by virtue of their location in the vicinity of targeted cells which have infiltrated the bone marrow.
- cytotoxic moieties such as toxins, or any immunotherapeutic which could damage healthy bone marrow progenitors by virtue of their location in the vicinity of targeted cells which have infiltrated the bone marrow.
- anti-CD20 antibodies are used, although antibodies to other B cell surface markers may also be used, e.g., anti-CD19 antibodies.
- the cell surface protein which is targeted should have the .characteristics of being expressed mainly on cancerous B cells and not generally on normal cells or B cell precursors, and preferably does not shed, internalize or modulate upon being bound by antibody.
- antibody fragment includes any therapeutically effective portion or derivative of a therapeutic antibody, which is effective to bind to the intended target and produce the intended result . Included are Fab 2 fragments, Fab fragments, Fv fragments, domain-deleted antibodies, etc.
- the antibodies used in the present invention are human, chimeric or humanized antibodies, such that the antibodies contain human constant region domains capable of stimulating human effector functions.
- a preferred antibody is the chimeric anti-CD20 antibody, Rituximab ® (marketed as Rituxan ® in the U.S. and Mabthera ® in Britain) .
- the patients who will most benefit from the present invention will be patients who have greater than 25% bone marrow involvement before being treated with the disclosed immunotherapy. Such patients may be identified by prior diagnostic imaging using antibodies radiolabeled with gamma-emitting isotopes such as X11 ln. Such patients may also be identified following bone marrow biopsy. According to a study by Wiseman et al . , such patients have a very high chance of developing thrombocytopenia due to radioimmunotherapy.
- any patient with any level of bone marrow involvement will benefit from the present invention in that they will benefit from a decreased risk of radioimmunotherapy-induced thrombocytopenia following the disclosed treatment.
- the dosages to be used in the present invention may vary depending on the patient, the extent of bone marrow involvement, and the antibody used.
- Chimeric anti-CD20 antibody such as Rituximab ® may be administered at a dosage of at least about 50 mg/m 2 weekly for at least 4 weeks.
- a preferred dosage regimen is about 375 mg/m 2 weekly for four weeks .
- the treatment methods of the present invention naturally encompass treatment with a radiolabeled antibody subsequent to purging of the marrow.
- the radiolabeled antibody may also be directed to any B cell surface marker which is found generally on cancerous cells and not normal cells.
- the radiolabeled antibody is an anti-CD20 antibody.
- Preferred radiolabels are beta emitting isotopes such as 90 Y or 131 I, but any radioisotope may be used so long as it may be effectively conjugated to the antibody, it has a relatively short decay range, and it succeeds in killing nearby cells, i.e., the cells to which it is targeted.
- a preferred radiolabeled anti- ,CD20 antibody is Y2B8.
- a patient should generally be treated within one week after administration of the depleting antibody, so long as they are not severely cytopenic, e.g., platelets ⁇ 150,000. If the patient is cytopenic following treatment with the depleting antibody, recovery should be allowed to occur, e.g.
- more depleting antibody may be administered directly before immunotherapy.
- Such a secondary dosage may be administered, for example, at about 250 mg/m 2 for about two weeks directly before or overlapping with radioimmunotherapy.
- Radiolabeled anti-CD20 antibodies like Y2B8 are administered at a dosage of about 0.1 to 0.5 mCi/kg. It, should be clear that the treatment methods disclosed herein may be combined with other known treatment methods such as chemotherapy or radiotherapy. Bone marrow or peripheral blood stem cells may be harvested from said patient subsequent to treatment with anti-CD20 antibody and prior to treatment with said radiolabeled antibody in order to effect autologous bone marrow or stem cell transplantation after radiotherapy.
- cytokines useful for this purpose are IL-4, GM-CSF and TNF-alpha. Cytokines may also be administered simultaneously with or prior to or subsequent to administration of the depleting antibody or radiolabeled antibody in order to stimulate immune effector functions. Cytokines useful for this purpose include interferon alpha, GM-CSF and G-CSF. Chemotherapeutic regimens may be used to supplement the therapies disclosed herein, and may be administered simultaneously with or sequentially in any order with administration of said radiolabeled antibody.
- the chemotherapy regimen may be selected from the group consisting of CHOP, ICE, Mitozantrone, Cytarabine, DVP, ATRA, Idarubicin, hoelzer chemotherapy regime, La La chemotherapy regime, ABVD, CEOP, 2-CdA, FLAG & IDA (with or without subsequent G-CSF treatment) , VAD, M & P, C- Weekly, ABCM, MOPP and DHAP .
- a preferred chemotherapeutic regimen is CHOP.
- the methods of the present invention may be used to treat a variety of B cell lymphomas but are particularly useful wherein said B cell lymphoma is non-Hodgkin' s lymphoma (NHL) .
- B cell lymphoma is non-Hodgkin' s lymphoma (NHL) .
- Rituximab ® has already been approved for the treatment of low-grade- follicular NHL, but the present inventors have surprisingly found that Rituximab ® is also beneficial for the treatment of intermediate- and high-grade NHL, including bulky disease.
- the lymphomas which are treatable by the methods of the present invention include low grade/ follicular non-Hodgkin' s lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/ follicular NHL, intermediate grade diffuse NHL, chronic lymphocytic leukemia (CLL) , high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small noneleaved cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma and Waldenstrom' s Macroglobulinemia, so long as such lymphomas are accompanied by bone marrow involvement which complicates the availability of radioimmunotherapy.
- NHL low grade/ follicular non-Hodgkin' s lymphoma
- SL small lymphocytic
- NHL intermediate grade/ follicular NHL
- intermediate grade diffuse NHL intermediate grade diffuse NHL
- CLL chronic lymphocytic leukemia
- high grade immunoblastic NHL high grade lymphoblastic NHL
- the MTD was 0.4 mCi/kg (0.3 mCi/kg for patients with mild thrombocytopenia) .
- Adverse events were mainly hematologic, transient and reversible.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001514978A JP2003513012A (en) | 1999-08-11 | 2000-07-25 | Treatment of patients with non-Hodgkin's lymphoma with bone marrow lesions by anti-CD20 antibodies |
AU76260/00A AU784971B2 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies |
CA002378646A CA2378646A1 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
MXPA02001398A MXPA02001398A (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies. |
EP00965561A EP1207906A4 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
NO20020639A NO20020639L (en) | 1999-08-11 | 2002-02-08 | Use of anti-CD20 antibody in the treatment of non-Hodgkins lymphoma involving bone marrow |
HK03101198.5A HK1048945A1 (en) | 1999-08-11 | 2003-02-18 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14828799P | 1999-08-11 | 1999-08-11 | |
US60/148,287 | 1999-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001010462A1 true WO2001010462A1 (en) | 2001-02-15 |
Family
ID=22525101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/040459 WO2001010462A1 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1207906A4 (en) |
JP (1) | JP2003513012A (en) |
CN (2) | CN101259270A (en) |
AU (1) | AU784971B2 (en) |
CA (1) | CA2378646A1 (en) |
HK (1) | HK1048945A1 (en) |
MX (1) | MXPA02001398A (en) |
MY (1) | MY136635A (en) |
NO (1) | NO20020639L (en) |
TW (1) | TWI279233B (en) |
WO (1) | WO2001010462A1 (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091657A2 (en) | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
US7740847B2 (en) | 2004-08-04 | 2010-06-22 | Applied Molecular Evolution, Inc. | Variant Fc regions |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2010074724A1 (en) * | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
US7799900B2 (en) | 2002-12-16 | 2010-09-21 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
EP2233149A1 (en) | 2007-10-16 | 2010-09-29 | ZymoGenetics, Inc. | Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease |
US7820161B1 (en) | 1999-05-07 | 2010-10-26 | Biogen Idec, Inc. | Treatment of autoimmune diseases |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
EP2272868A2 (en) | 2003-06-05 | 2011-01-12 | Genentech, Inc. | Combination therapy for B cell disorders |
WO2011019619A1 (en) | 2009-08-11 | 2011-02-17 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
EP2295080A2 (en) | 2005-07-25 | 2011-03-16 | Trubion Pharmaceuticals, Inc. | B-cell reduction using CD37-specific and CD20-specific binding molecules |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
EP2415483A1 (en) | 2005-07-25 | 2012-02-08 | Emergent Product Development Seattle, LLC | Single dose use of cd20-specific binding molecules |
US8333966B2 (en) | 2008-04-11 | 2012-12-18 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutics and uses thereof |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
EP2586788A1 (en) | 2007-07-09 | 2013-05-01 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
US8529902B2 (en) | 2002-10-17 | 2013-09-10 | Genmab A/S | Human monoclonal antibodies against CD20 |
US20130309244A1 (en) * | 2010-12-21 | 2013-11-21 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
US8653064B2 (en) | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
US8883980B2 (en) | 2003-11-05 | 2014-11-11 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
US9005612B2 (en) | 2001-01-17 | 2015-04-14 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
US9127011B2 (en) | 2009-07-31 | 2015-09-08 | Millennium Pharmaceuticals, Inc. | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
WO2016118353A1 (en) * | 2015-01-23 | 2016-07-28 | Immunomedics, Inc. | Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma |
US9416187B2 (en) | 2003-05-09 | 2016-08-16 | Duke University | CD-20 specific antibodies and methods of employing same |
EP3095463A2 (en) | 2008-09-16 | 2016-11-23 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
WO2016196344A1 (en) | 2015-05-30 | 2016-12-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
EP3130349A1 (en) | 2004-06-04 | 2017-02-15 | Genentech, Inc. | Method for treating multiple sclerosis |
WO2017055542A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
US9724354B2 (en) | 2013-03-22 | 2017-08-08 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase |
US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
US10450379B2 (en) | 2005-11-15 | 2019-10-22 | Genetech, Inc. | Method for treating joint damage |
US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019529433A (en) * | 2016-09-16 | 2019-10-17 | ノルディック ナノベクター アルメン アクスイェ セルスカプ | Non-Hodgkin Lymphoma Treatment Method Using Lilotomab and 177Lu-Lilotomab Satetraxetane |
CN108421048B (en) * | 2016-09-28 | 2021-04-20 | 首都医科大学附属北京世纪坛医院 | Nano active carbon targeted drug delivery system, preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5843439A (en) * | 1992-11-13 | 1998-12-01 | Anderson; Darrell R. | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1320044A (en) * | 1998-08-11 | 2001-10-31 | Idec药物公司 | Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody |
US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) * | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
-
2000
- 2000-07-25 AU AU76260/00A patent/AU784971B2/en not_active Expired
- 2000-07-25 EP EP00965561A patent/EP1207906A4/en not_active Withdrawn
- 2000-07-25 WO PCT/US2000/040459 patent/WO2001010462A1/en active Application Filing
- 2000-07-25 MX MXPA02001398A patent/MXPA02001398A/en active IP Right Grant
- 2000-07-25 JP JP2001514978A patent/JP2003513012A/en active Pending
- 2000-07-25 CN CNA2008100921383A patent/CN101259270A/en active Pending
- 2000-07-25 CN CNB008116644A patent/CN100389825C/en not_active Expired - Lifetime
- 2000-07-25 CA CA002378646A patent/CA2378646A1/en not_active Abandoned
- 2000-08-03 MY MYPI20003551A patent/MY136635A/en unknown
- 2000-08-10 TW TW089116114A patent/TWI279233B/en not_active IP Right Cessation
-
2002
- 2002-02-08 NO NO20020639A patent/NO20020639L/en not_active Application Discontinuation
-
2003
- 2003-02-18 HK HK03101198.5A patent/HK1048945A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843439A (en) * | 1992-11-13 | 1998-12-01 | Anderson; Darrell R. | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
Non-Patent Citations (6)
Title |
---|
BEHR ET AL.: "Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies", CLIN. CAN. RES., vol. 5, October 1999 (1999-10-01), pages 3304S - 3314S, XP002935649 * |
GOPAL ET AL.: "Clinical applications of anti-CD20 antibodies", J. LAB. CLIN. MED., vol. 134, no. 5, November 1999 (1999-11-01), pages 445 - 450, XP002935646 * |
MALONEY ET AL.: "Newer treatments for Non-Hodgkin's lymphoma: Monoclonal antibodies", ONCOLOGY, vol. 12, no. 10, October 1998 (1998-10-01), pages 63 - 76, XP002935647 * |
See also references of EP1207906A4 * |
WISEMAN ET AL.: "Radioimmunotherapy of relapsed Non-Hodgkin's lymphoma with Zevalin, a Y-labled anti-CD20 monoclonal antibody", CLIN. CAN. RES., vol. 5, October 1999 (1999-10-01), pages 3281S - 3286S, XP002935648 * |
WITZIG ET AL.: "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell Non-Hodgkin's lymphoma", J. CLIN. ONCOL., vol. 17, no. 12, December 1999 (1999-12-01), pages 3793 - 3803, XP002935650 * |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820161B1 (en) | 1999-05-07 | 2010-10-26 | Biogen Idec, Inc. | Treatment of autoimmune diseases |
US9993550B2 (en) | 1999-05-07 | 2018-06-12 | Genentech, Inc. | Treatment of pemphigus |
US8545843B2 (en) | 1999-05-07 | 2013-10-01 | Genentech, Inc. | Treatment of vasculitis |
US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
US9005612B2 (en) | 2001-01-17 | 2015-04-14 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
US8529902B2 (en) | 2002-10-17 | 2013-09-10 | Genmab A/S | Human monoclonal antibodies against CD20 |
US7799900B2 (en) | 2002-12-16 | 2010-09-21 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
EP2062916A2 (en) | 2003-04-09 | 2009-05-27 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
WO2004091657A2 (en) | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
US7708994B2 (en) | 2003-04-09 | 2010-05-04 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor |
US7976838B2 (en) | 2003-04-09 | 2011-07-12 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor |
US9416187B2 (en) | 2003-05-09 | 2016-08-16 | Duke University | CD-20 specific antibodies and methods of employing same |
EP2272868A2 (en) | 2003-06-05 | 2011-01-12 | Genentech, Inc. | Combination therapy for B cell disorders |
US8883980B2 (en) | 2003-11-05 | 2014-11-11 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
EP3130349A1 (en) | 2004-06-04 | 2017-02-15 | Genentech, Inc. | Method for treating multiple sclerosis |
US7740847B2 (en) | 2004-08-04 | 2010-06-22 | Applied Molecular Evolution, Inc. | Variant Fc regions |
EP2298815A1 (en) | 2005-07-25 | 2011-03-23 | Trubion Pharmaceuticals, Inc. | B-cell reduction using CD37-specific and CD20-specific binding molecules |
EP2295080A2 (en) | 2005-07-25 | 2011-03-16 | Trubion Pharmaceuticals, Inc. | B-cell reduction using CD37-specific and CD20-specific binding molecules |
EP2415483A1 (en) | 2005-07-25 | 2012-02-08 | Emergent Product Development Seattle, LLC | Single dose use of cd20-specific binding molecules |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
EP2586798A2 (en) | 2005-07-25 | 2013-05-01 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
US10450379B2 (en) | 2005-11-15 | 2019-10-22 | Genetech, Inc. | Method for treating joint damage |
US10654940B2 (en) | 2005-11-15 | 2020-05-19 | Genentech, Inc. | Method for treating joint damage |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
EP4245766A2 (en) | 2007-07-09 | 2023-09-20 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP3597659A1 (en) | 2007-07-09 | 2020-01-22 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP4335863A2 (en) | 2007-07-09 | 2024-03-13 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP3327026A1 (en) | 2007-07-09 | 2018-05-30 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP4219522A2 (en) | 2007-07-09 | 2023-08-02 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP2586788A1 (en) | 2007-07-09 | 2013-05-01 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP4365189A2 (en) | 2007-07-09 | 2024-05-08 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP2233149A1 (en) | 2007-10-16 | 2010-09-29 | ZymoGenetics, Inc. | Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
US8333966B2 (en) | 2008-04-11 | 2012-12-18 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutics and uses thereof |
US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US9683047B2 (en) | 2008-09-16 | 2017-06-20 | Genentech, Inc. | Methods for treating progressive multiple sclerosis |
EP4364800A2 (en) | 2008-09-16 | 2024-05-08 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
EP3747464A1 (en) | 2008-09-16 | 2020-12-09 | F. Hoffmann-La Roche AG | Methods for treating progessive multiple sclerosis using an anti-cd20 antibody |
EP3095463A2 (en) | 2008-09-16 | 2016-11-23 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
US9994642B2 (en) | 2008-09-16 | 2018-06-12 | Genentech, Inc. | Methods for treating progressive multiple sclerosis |
KR101741168B1 (en) | 2008-12-22 | 2017-05-29 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2010074724A1 (en) * | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
US10391100B2 (en) | 2008-12-22 | 2019-08-27 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
US9127011B2 (en) | 2009-07-31 | 2015-09-08 | Millennium Pharmaceuticals, Inc. | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
US9504693B2 (en) | 2009-07-31 | 2016-11-29 | Millennium Pharmaceuticals, Inc. | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
US10982003B2 (en) | 2009-08-11 | 2021-04-20 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
US9714293B2 (en) | 2009-08-11 | 2017-07-25 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
EP3760712A1 (en) | 2009-08-11 | 2021-01-06 | F. Hoffmann-La Roche AG | Production of proteins in glutamine-free cell culture media |
WO2011019619A1 (en) | 2009-08-11 | 2011-02-17 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
US10017513B2 (en) | 2010-02-19 | 2018-07-10 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate |
US8653064B2 (en) | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
US20130309244A1 (en) * | 2010-12-21 | 2013-11-21 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
US10611999B2 (en) | 2012-09-06 | 2020-04-07 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
US9724354B2 (en) | 2013-03-22 | 2017-08-08 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase |
WO2016118353A1 (en) * | 2015-01-23 | 2016-07-28 | Immunomedics, Inc. | Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma |
EP3636660A1 (en) | 2015-05-30 | 2020-04-15 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
WO2016196344A1 (en) | 2015-05-30 | 2016-12-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
EP3660035A1 (en) | 2015-05-30 | 2020-06-03 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
WO2017055542A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
US12030952B2 (en) | 2015-10-02 | 2024-07-09 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
Also Published As
Publication number | Publication date |
---|---|
AU7626000A (en) | 2001-03-05 |
MY136635A (en) | 2008-11-28 |
TWI279233B (en) | 2007-04-21 |
JP2003513012A (en) | 2003-04-08 |
EP1207906A4 (en) | 2005-07-06 |
CA2378646A1 (en) | 2001-02-15 |
NO20020639D0 (en) | 2002-02-08 |
EP1207906A1 (en) | 2002-05-29 |
MXPA02001398A (en) | 2002-08-12 |
AU784971B2 (en) | 2006-08-10 |
CN101259270A (en) | 2008-09-10 |
CN1373671A (en) | 2002-10-09 |
CN100389825C (en) | 2008-05-28 |
HK1048945A1 (en) | 2003-04-25 |
NO20020639L (en) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784971B2 (en) | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies | |
US10400043B2 (en) | Treatment of diffuse large-cell lymphoma with anti-CD20 antibody | |
JP6226216B2 (en) | Combination therapy of B cell lymphoma including administration of anti-CD20 antibody | |
US20040213784A1 (en) | Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant | |
AU2017219596A1 (en) | Chimeric canine anti-CD20 antibody | |
KR20200010472A (en) | Therapeutic Paradigm for Combination Therapy with Anti-CD19 Antibody and Venetoclax | |
AU2005211669B2 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
TWI280137B (en) | Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
EP2264070A1 (en) | Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 76260/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2378646 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/001398 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008116644 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000965561 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000965561 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |